RARE compared with CMPS: revenue, margins and what each company keeps, and the suppliers and customers both name

RAREUltragenyx Pharmaceutical Inc.

Mkt capRevenueRevenue

CMPSCOMPASS Pathways plc

Mkt capRevenueRevenue

Compare

RAREUltragenyx Pharmaceutical Inc.

CMPSCOMPASS Pathways plc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

RARE1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±16.4%▼−3.41%×0.21

CMPS

No earnings history for CMPS.

= impliedRARE realized, solidCMPS realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

RAREUltragenyx Pharmaceutical Inc.

16.10▼−4.05%· post 16.06

Mkt cap$1.6BRevenue$214MQ2 FY26Revenue$673MFY25

CMPSCOMPASS Pathways plc

11.57▼−5.09%· post 11.62

ClosedOct 30 '26

Mkt cap$1.6BRevenue—Revenue—

Compare

ClosedOct 30 '26

RAREUltragenyx Pharmaceutical Inc.

CMPSCOMPASS Pathways plc

16.10▼−4.05%post 16.06

Price

11.57▼−5.09%post 11.62

$1.6B

Mkt cap

$1.6B

Q2 FY26$214M

Revenue

—

FY25$673M

Revenue

—

RARE16.10▼−4.05%vsCMPS11.57▼−5.09%ClosedOct 30 '26